Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Lacking in Trials
Author(s):
San Francisco - Despite the importance of knowing which of the numerous treatment modalities should be used as first-line treatment for basal cell carcinoma (BCC), there is a severe lack of well-designed, randomized, controlled trials to evaluate the different treatment options, according to Jan Bong, M.B., C.H.B., M.R.C.P., of Queen's Medical Centre, University of Nottingham.
Related Videos
Related Content
